Rivastigmine (Standard)

Rivastigmine (Standard) is the analytical standard of Rivastigmine. This product is intended for research and analytical applications. Rivastigmine (ENA 713 free base) is an orally active and potent cholinesterase (ChE) inhibitor and inhibits butyrylcholinesterase (BChE) and acetylcholinesteras (AChE) with IC50s of 0.037 μM , 4.15 μM, respectively. Rivastigmine can pass the blood brain barrier (BBB) . Rivastigmine is a parasympathomimetic or cholinergic agent used for the research of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease[1][2].

Product Specifications

CAS Number

[123441-03-2]

Product Name Alternative

ENA 713 (free base) (Standard) ; SDZ-ENA 713 (free base) (Standard)

UNSPSC

12352005

Hazard Statement

H300, H411

Target

Cholinesterase (ChE) ; Reference Standards

Type

Reference Standards

Related Pathways

Neuronal Signaling; Others

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/rivastigmine-standard.html

Purity

99.96

Smiles

O=C(OC1=CC=CC([C@@H](N(C)C)C)=C1)N(CC)C

Molecular Formula

C14H22N2O2

Molecular Weight

250.34

Precautions

H300, H411

References & Citations

[1]Qian-Sheng Yu, et al. Anticholinesterase activity of compounds related to geneserine tautomers. N-Oxides and 1,2-oxazines. J Med Chem. 2002 Aug 15;45 (17) :3684-91.|[2]Han HJ, Lee JJ, Park SA et al. Efficacy and safety of switching from oral cholinesterase inhibitors to the rivastigmine transdermal patch in patients with probable Alzheimer's disease. J Clin Neurol. 2011 Sep;7 (3) :137-42.|[3]Helena Shifrin, et al. Rivastigmine alleviates experimentally induced colitis in mice and rats by acting at central and peripheral sites to modulate immune responses. PLoS One. 2013;8 (2) :e57668.|[4]Raafat A Abdel-Aal, et al. Rivastigmine reverses aluminum-induced behavioral changes in rats. Eur J Pharmacol. 2011 Jun 1;659 (2-3) :169-76.